MedX Health Corp. (TSX-V:MDX) has announced the appointment of Naman Demaghlatrous as the company’s new president and CEO, effective immediately.
MedX said Demaghlatrous has more than 20 years of healthcare and pharmaceutical industry experience, having served in senior roles with medical and pharma companies in Europe and North America.
“Globalizing MedX’s offering now that we have a proven methodology of pilot project to commercial contract is the next step,” Demaghlatrous said in a statement.
READ: MedX Health closes first tranche of the non-brokered private placement with the issuance of 20 convertible loan notes which raised a total of $1M
“Penetrating new verticals, strengthening the team, while continuing to leverage our market access, training and education as well as our regulatory resources will both expand our footprint and accelerate our revenue growth,” he added.
The company noted that Demaghlatrous joined MedX in 2021 as managing director, Europe, Middle East and Africa Operations, and has been focused on developing and expanding the company’s global market opportunities, and establishing distribution partnerships and adoption in Europe and North America of the MedX Dermsecure platform and related technology.
It added that former CEO Sylvain Desjeans will remain a MedX director.
MedX Health is a global leader in teledermatology through its high-definition image capture technology, SIAscopy, and its secure, cloud-based patient management system, DermSecure, which transmits and stores patient data throughout the assessment process.
The company’s leading telemedicine platform allows health-care practitioners to quickly and accurately assess suspicious moles, lesions and other skin conditions via its image-capture technology.
Contact Sean at sean@proactiveinvestors.com